drugset
drugset / Trial / NCT02711345

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

NCT02711345 ↗

Phase 1 Terminated 65 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.

Timeline

Start
2016-04-15
Primary completion
2018-11-21
Completion
2018-11-21

Outcome

Outcome not reported

Stopped: “considering the limited clinical activity observed with LTT462, the decision was made to not open the dose expansion phase of the study”

Drugs

EvaluationDrugModalityDoseRoute
Subject LTT462 Unknown — Oral

Indications

melanoma non-small cell lung carcinoma ovarian neoplasm